April 18, 2018 / 7:21 AM / 7 months ago

BRIEF-NeuroVive Receives FDA Orphan Drug Designation

1 Min Read

April 18 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:

* NEUROVIVE’S KL1333 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR TREATMENT OF MITOCHONDRIAL DISEASES

* ODD OPENS UP FOR MARKET EXCLUSIVITY FOR SEVEN YEARS WITHIN US FOR NEUROVIVE’S KL1333, WHEN AUTHORISED FOR MARKETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below